Observational studyFrontiers in endocrinology2026
The estradiol-to-periovulatory follicle ratio (E2/N16) as a marker of follicular endocrine efficiency and embryological outcomes in ART cycles.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Controlled ovarian stimulation (COS) in assisted reproductive technology (ART) is traditionally assessed using quantitative parameters, particularly the number of retrieved oocytes. However, these measures may not fully capture the endocrine efficiency of the periovulatory follicular cohort. Objective: To evaluate the association between the estradiol-to-periovulatory follicle ratio (E2/N16) and embryo yield, and to investigate its relationship with serum progesterone concentrations and ovarian stimulation characteristics. Methods: This retrospective observational cohort study included 2,831 ART cycles performed between January 2022 and February 2025. E2/N16 was calculated by dividing serum estradiol concentration by the number of periovulatory follicles (≥16 mm) on the day of trigger. The primary outcome was viable embryo yield per cycle. E2/N16 was analyzed as a continuous variable and by quartiles. Multivariable models were adjusted for female age, body mass index, anti-Müllerian hormone, number of retrieved oocytes, total FSH dose, and trigger type. Restricted cubic splines with formal tests of non-linearity and sensitivity analyses were also performed. Results: Viable embryo yield progressively decreased across increasing E2/N16 quartiles, from 2.09 to 1.77 embryos per cycle (p < 0.001). After multivariable adjustment, including trigger type, higher E2/N16 remained independently associated with lower embryo yield (β = -0.000218; 95% CI, -0.000427 to -0.000010; p = 0.040). The spline showed no statistically significant departure from linearity (P for non-linearity = 0.449), despite a modest initial rise followed by a decline. The association with serum progesterone was significantly non-linear (P for non-linearity = 0.009), with a U-shaped pattern. After exclusion of cycles with two or fewer periovulatory follicles, the association with embryo yield was attenuated but remained directionally consistent. Conclusions: The estradiol-to-periovulatory follicle ratio (E2/N16) was independently associated with embryo yield and provided information complementary to conventional quantitative measures of ovarian response. Its relationship with progesterone was non-monotonic, indicating that E2/N16 should not be interpreted as a simple linear marker of ovarian steroidogenesis. Prospective studies are required to validate its clinical utility and define how it might contribute to the assessment of ovarian stimulation in ART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.